Comparison · NCT02553330-sae
Ruxolitinib Cream vs Placebo Cream: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ruxolitinib Cream vs Placebo Cream: serious adverse events. Trial comparisons, record NCT02553330-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02553330-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0482 | 0.0189 | 0.117 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0918 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0482 | -0.0482 | 0.117 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm, for one more participant with a serious adverse event on Ruxolitinib Cream than on Placebo Cream | 20.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ruxolitinib Cream | Part A: Open-label treatment for 24 weeks. Part B: Double-blind treatment for 24 weeks. Placebo group from Part B had the option to crossover after the first 24 weeks of treatment period.~Both Part A and Part B participants, if eligible, continued on to open-label extension (24 weeks) and long-term extension (48 weeks) periods. | 4 | 83 | EG001 |
| Group 2 | Placebo Cream | Part B: Double-blind treatment for 24 weeks. | 0 | 38 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 100 weeks
Source ClinicalTrials.gov
Trial
- Title
- A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
- NCT number
- NCT02553330
- Phases
- PHASE2
- Conditions
- Alopecia Areata
- Interventions
- Placebo Cream, Ruxolitinib Phosphate Cream
- Lead sponsor
- Incyte Corporation
- Results first posted
- 2020-12-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02553330?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02553330-sae